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Self-renewal and differentiation of stem cells are
fundamentally associated with cell-cycle progres-
sion to enable tissue specification, organ homeo-
stasis, and potentially tumorigenesis. However,
technical challenges have impaired the study of the
molecular interactions coordinating cell fate choice
and cell-cycle progression. Here, we bypass these
limitations by using the FUCCI reporter system in
human pluripotent stem cells and show that their
capacity of differentiation varies during the progres-
sion of their cell cycle. These mechanisms are gov-
erned by the cell-cycle regulators cyclin D1–3 that
control differentiation signals such as the TGF-
b-Smad2/3 pathway. Conversely, cell-cycle manipu-
lation using a small molecule directs differentiation of
hPSCs and provides an approach to generate cell
types with a clinical interest. Our results demonstrate
that cell fate decisions are tightly associated with the
cell-cycle machinery and reveal insights in the mech-
anisms synchronizing differentiation and prolifera-
tion in developing tissues.
INTRODUCTION
Tissue differentiation and maintenance is ultimately regulated by
the coordination between differentiation and proliferation of spe-
cific stem cells or progenitors. The importance of these mecha-
nisms has been well documented in early development and in a
diversity of organs such as the skin, brain, gut, and hematopoi-
etic system (Fuchs, 2009; Lange and Calegari, 2010; Li and
Clevers, 2010). However, the molecular regulations coordinating
cell-cycle progression and differentiation remain unclear. The
study of such mechanisms with adult stem cells in vivo is
challenging for technical reasons, whereas in vitro expansion
of these cells remains difficult. Human pluripotent stem cells
(hPSCs) generated from embryo at the blastocyst stage (embry-
onic stem cells or hESCs) or from reprogrammed somatic cells
(induced pluripotent stem cells or hIPSCs) represent an advanta-
geous system to model these regulations because they can
proliferate indefinitely in vitro while maintaining the capacity todifferentiate into the three primary germ layers, neuroectoderm,
mesoderm, and endoderm. Furthermore, mechanismsmaintain-
ing the pluripotent status of hPSCs and orchestrating their cell
fate specification have been broadly studied. Activin/Nodal
and FGF cooperate to maintain the expression of pluripotency
factors, including Nanog, that in turn block neuroectoderm
differentiation (Vallier et al., 2009a; Xu et al., 2008). Accordingly,
inhibition of Activin/Nodal signaling induces neuroectoderm
differentiation (Chambers et al., 2009). However, Activin/Nodal
signaling is also necessary for endoderm differentiation and
achieves these apparent contradictory functions by controlling
divergent transcriptional networks in pluripotent cells and during
endoderm specification (Brown et al., 2011; Mullen et al., 2011).
Thus, the activity of Activin/Nodal needs to be tightly controlled
in hPSCs and factors influencing this activity can direct their
differentiation either toward neuroectoderm or mesendoderm
(Chng et al., 2010).
Pluripotency is also linked with cell-cycle regulation because
studies in mouse ESCs (mESCs) have shown that their pluripo-
tent status is associated with a specific cell-cycle profile charac-
terized by a shortened G1 phase and the lack of G1 checkpoint
regulation (Coronado et al., 2013; Savatier et al., 1996). In con-
ventional cells, cyclin D1–3 are expressed in G1 phase and con-
trol the activity of CDK4/6 that inhibit pRB and free E2F to initiate
the G1-S transition. In contrast, cyclin Ds are expressed at low
level in mESCs, whereas pRB is constitutively phosphorylated
byCDK2-cyclin E bypassing the need of a G1 checkpoint (Savat-
ier et al., 1994). hESCs are also characterized by a short G1
phase, whereas their pluripotent status relies on CDK2 activity
(Neganova et al., 2009). Furthermore, both hESCs and mESCs
display the same resistance to DNA damage suggesting a similar
lack in G1 check points (Neganova et al., 2011). However, the
mechanisms involved might diverge as indicated by the expres-
sion of cyclin D proteins (Neganova et al., 2009) and the pres-
ence of normal pRB-cyclin Ds/CDK4/6 cascade in hESCs (Sela
et al., 2012). This difference could be explained by species diver-
gence but also by a different embryonic origin, mESCs repre-
senting the inner cell mass of preimplantation blastocyst in
diapause, whereas hESCs being more similar to epiblast cells
of postimplantation embryo (Brons et al., 2007; Tesar et al.,
2007). Nevertheless, recent studies have clearly shown that
both mouse and human pluripotent stem cells exhibit a length-
ening of the G1 phase during differentiation, indicating that dif-
ferentiation affects cell-cycle regulation and that a truncatedCell 155, 135–147, September 26, 2013 ª2013 Elsevier Inc. 135
G1 phase is a hallmark of the pluripotent state (Calder et al.,
2013; Coronado et al., 2013). Besides these observations, the
potential interconnections between cell fate choice and cell-
cycle progression have remained largely unstudied due to the
lack of molecular tools for investigating cell-cycle mechanisms
in pluripotent cells. Indeed, cell synchronization using chemical
inhibitors in ESCs systematically induces their differentiation,
whereas serum deprivation has no effect (Sela et al., 2012).
In this study, we took advantage of the FUCCI (Sakaue-
Sawano et al., 2008) reporter system to study the regulation of
cell fate choice in hESCs and their capacity to differentiate into
chemically defined culture conditions promoting endoderm,
mesoderm, and neuroectoderm specification. We observed
that hESCs in early G1 phase can only initiate differentiation
into endoderm, whereas hESCs in late G1 were limited to neuro-
ectoderm differentiation. Functional experiments reveal that the
activity of Activin/Nodal signaling during cell-cycle progression
is controlled by cyclin D proteins that activate CDK4/6 and
lead to the phosphorylation of Smad2 and Smad3 in their linker
region. This mechanism blocks Smad2/3 shuttling in the nucleus
in late G1, thereby preventing endoderm and allowing neuroec-
toderm specification. Thus, cyclin D proteins act as essential
regulators of signaling pathways controlling early cell fate
decisions. These results unravel the molecular mechanisms by
which cell fate decisions are controlled by the cell-cycle machin-
ery and uncover how self-renewal and pluripotency could be
coordinated.
RESULTS
Generation of FUCCI-hESC Reporter Lines for Studying
Cell-Cycle Progression
Analysis of cell-cycle-specific events in pluripotent cells is chal-
lenging because cell-cycle synchronization using chemicals in-
duces their differentiation (data not shown). To overcome this
limitation, we decided to adapt the FUCCI reporter system to
hESCs (Figure 1A) grown in fully defined culture conditions
(Vallier et al., 2005). We first subcloned the Geminin-mAG and
Cdt-mKO2 fusion genes in the pTP6 system that enables stable
transgene expression based on Puromycin or Neomycin resis-
tance (Vallier et al., 2004). The resulting vectors were cotrans-
fected in hESCs using Lipofectamine 2000 as described
previously (Vallier et al., 2004). Following antibiotics selection,
we picked individual hESC colonies containing green, red, and
yellow fluorescent cells for further analyses (Figure 1B and Fig-
ure S1A available online). Of note, the resulting subclonal
FUCCI-hESCs were grown in the presence of Puromycin and
Neomycin to guarantee constant and homogenous expression
of the reporter genes.
We first performed time-lapse microscopy on single FUCCI-
hESC and observed the expected transition from red to green
fluorescence upon progression of the cell cycle (Figure 1C).
Furthermore, fluorescence-activated cell sorting (FACS) ana-
lyses combined with Hoechst staining showed that FUCCI-
hESCs have the same cell-cycle profile as nontransfected
hESCs (Figure 1D) demonstrating that transgene overexpression
did not alter cell-cycle regulation. These analyses also confirm
that the fluorescent proteins were expressed as expected during136 Cell 155, 135–147, September 26, 2013 ª2013 Elsevier Inc.the cell cycle (Figures 1E and 1F: green fluorescent cells in G2,
nonfluorescent cells in early G1, red fluorescent in late G1, and
yellow fluorescent cells in G1/S). Furthermore, FACS analyses
showed that sorted FUCCI-hESCs express pluripotency factors
homogenously (95% Oct-4+ cells) independently of their cell
cycle, whereas differentiation markers such as Sox1 (<1%) or
Sox17 (<4%) were expressed in a small fraction of cells distrib-
uted equally in the different phases of the cell cycle (Figures
S1D and S1E; data not shown). Similar results have been
obtained with Nanog, Tra-1-60, Eomes, Mixl1, Goosecoid, and
Pax6 (data not shown), confirming that hESCs in our culture sys-
tem grow as a near-homogenous population with a minimal
background of differentiation. Considered collectively, these
results demonstrate the efficacy of the FUCCI reporter system
to sort hESCs into different phases of their cycle without altering
their fundamental characteristics.
Differentiation Capacity of hESCs Varies during
Progression of the G1 Phase
Previous studies have shown that cell fate decisions could be
made during the G1 phase (Calder et al., 2013; Sela et al.,
2012). To investigate this possibility in more detail, we examined
the capacity of hESCs to respond to differentiation signals at
different phases of the cell cycle. For that, Tra-1-60-positive
FUCCI-hESCs were sorted according to their fluorescence and
then placed in defined culture conditions driving differentiation
into homogenous populations of endoderm,mesoderm and neu-
roectoderm cells (Vallier et al., 2009b, 2009c). This analysis re-
vealed that hESCs in early G1 could only initiate endoderm/
mesoderm gene expression (see Mixl1, Goosecoid, Eomes, T,
Mesp1, TBX6, HAND1, Mesp2; Figures 2A and 2B; Table S1),
whereas hESCs in late G1 could only initiate the expression of
neuroectoderm markers (see Sox1, Sip1, Gbx2, Olig3; Fig-
ure 2C). On the other hand, cells in G2/S/M phases of the cell
cycle responded poorly to differentiation signals (Figures 2A–
2C). These results confirm that induction of differentiation in
hESCs occurs during the G1 phase of the cell cycle but also
reveal that hESCs in early and late G1 might have a different
capacity of differentiation.
Because these experiments represent an early snapshot of
gene transcription after only 6 hr of differentiation, we decided
to investigate the capacity of sorted FUCCI-hESCs to dif-
ferentiate into neuroectoderm and endoderm over a prolonged
period of time. FACS and quantitative PCR (qPCR) analyses
showed that early G1 hESCs differentiated into a near-
homogenous population of endoderm cells (85% Sox17+/80%
CXCR4+/3% Oct4+; Figures 2D, 2F, and S1D) in 48 hr, whereas
unsorted hESCs (35% Sox17+/40% CXCR4+/23% Oct4+; Fig-
ures 2D, 2F and S1B) or late G1-hESCs (5% Sox17/4%
CXCR4+/80% Oct4; Figures 2D, 2F, and S1B) grown in the
same conditions remained a heterogeneous population of cells.
The opposite results were obtained for neuroectoderm differen-
tiation (Figures 2E, 2G, S1C, and S1E). These observations
confirmed that hESCs display different capacity of differentiation
upon the progression of the G1 phase. Early G1-hESCs are
permissive for initiating endoderm specification, whereas late
G1-hESCs are permissive for neuroectoderm differentiation
(Figure S1F).
Figure 1. Generating Fucci-hESCs for Studying Cell-Cycle-Dependent Events in Live Pluripotent Stem Cells
(A) Mechanistic overview of the FUCCI system. FUCCI system relies on the fusion of a red and green fluorescent protein (red mKO2 and green mAG) to two cell-
cycle-specific proteins (Cdt1 and Geminin).
(B) Representative colony of FUCCI-hESCs showing cells in early G1 (no fluorescence), late G1 (red), G1/S transition (yellow), and S/G2/M (green). Scale bar
represents 100 mm.
(C) Time-lapse imaging of a FUCCI-hESC progressing through the cell cycle. Early G1 cells express neither red mKO2-Cdt1 nor green mAG-Geminin. Late G1
cells express red mKO2-Cdt1. mAG-Geminin starts being expressed in G1/S transition giving the cells a temporal yellow color due to coexpression with mKO2-
Cdt1. Cells in S, G2, and M phase expressing only the green mAG-Geminin. During cell division, mAG-Geminin is rapidly degraded and the resulting daughter
cells are not fluorescent (arrows). Scale bar represents 5 mm.
(D) FUCCI system does not alter the cell-cycle distribution of hESCs. H9 hESCs and FUCCI-hESCs were analyzed for DNA content by flow cytometry and
Hoechst staining.
(E) Analysis of the relative proportion of FUCCI-hESCs in each cell-cycle phase. FUCCI-hESCs were analyzed by flow cytometry for mAG-Geminin (FL1) and
mKO2-Cdt1 (FL2) expression.
(F) DNA content analysis of different cell-cycle phases in FUCCI-hESCs. FUCCI-hESCs were stained with Hoechst and subpopulations of cells were gated as
shown in (E). Green, early G1 phase; blue, late G1 phase; light blue, G1/S transition; orange, S/G2/M phase; red, total population.The Efficiency of hESCs to Differentiate into Tissue-
Specific Cells Is Influenced by Their Cell Cycle
The results described above do not exclude the possibility to
generate homogenous populations of differentiated cells from
hESCs as we and others have shown (Vallier et al., 2009b).
Indeed, hESCs grown in inductive culture conditions are
constantly cycling and thus sooner or later receive signals initi-
ating their differentiation. Accordingly, unsorted FUCCI-hESCs
generate populations of endoderm cells expressing homoge-
nously Sox17/CXCR4 (95% + cells; data not shown) after 80 hr
of differentiation. However, our observations could explain why
differentiation of hESCs is always asynchronous with cells upre-
gulating differentiation markersmore rapidly than others (Figures
2D, 2F and S1B). Indeed, a late G1-hESC will delay the initiation
of its differentiation toward the endoderm lineage for an addi-
tional cell cycle (30 hr) before reaching the next early G1 phase.
This mechanism would result in a population of cells differenti-ating toward the same lineage but at varying developmental
stages. This hypothesis also implies that a cell in a specific phase
of the cell cycle could lose its capacity to differentiate toward
other lineages more rapidly.
To validate this point, Tra-1-60-positive FUCCI-hESCs sorted
into early G1 or late G1 were grown in conditions inductive for
endoderm differentiation for 12 hr and then for an additional
72 hr in conditions inductive for neuroectoderm differentiation
(Figure 2H). qPCR analyses showed that early G1 hESCs
induced to differentiate toward endoderm lose their capacity to
express neuroectoderm markers contrary to late G1 hESCs
grown in similar culture conditions (Figure 2H). These results
confirmed that early G1-hESCs can differentiate more rapidly
into endoderm than cells in late G1 and validate in part our
hypothesis concerning the link between asynchronous dif-
ferentiation of pluripotent cells and their cell-cycle state. These
results also suggest that hESCs synchronized in early G1 couldCell 155, 135–147, September 26, 2013 ª2013 Elsevier Inc. 137
(legend on next page)
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differentiate more efficiently into endoderm derivatives. This
prompted us to investigate the importance of the cell cycle for
the production of terminally differentiated cells such as pancre-
atic and hepatic cells. hESCs synchronized in early G1 or late
G1 were differentiated into both cell types using defined culture
conditions as described previously (Cho et al., 2012). qPCR and
immunostaining analyses showed that early G1-hESCs were
able to differentiate more efficiently into insulin-expressing cells
and hepatocyte-like cells when compared to unsorted cells or
cells sorted in late G1 as shown by the increase in the number
of c-peptide-positive cells and in the expression of endocrine
markers for pancreatic differentiation (Ngn3, Insulin, and
Glucagon; Figures 2J and 2L) and the increase in the expression
of hepatocytes markers for hepatic differentiation (FoxA2,
Albumin, AFP, HNF4a, and A1AT; Figures 2K and 2M). Taken
together, these results demonstrate that the phase of the cell
cycle during which hESCs initiate their differentiation can influ-
ence their capacity to generate differentiated cells and under-
lines the importance of cell-cycle regulation in the mechanisms
controlling cell fate decisions.
Cyclin Ds Are Necessary to Maintain Pluripotency of
hESCs by Preventing Endoderm Differentiation Induced
by Activin/Nodal Signaling
The capacity of hESCs to initiate their differentiation toward the
endoderm lineage during the early G1 phase suggest that
signaling pathways inducing this differentiation might be more
active during this phase of the cell cycle. Activin/Nodal signaling
has been shown to be the main inducer of endoderm differenti-
ation (D’Amour et al., 2005). Therefore, we decided to define
the transcriptional activity of Activin/Nodal-Smad2/3 signaling
during cell-cycle progression of hESCs. We first performed
Smad2/3 chromatin immunoprecipitation (ChIP) on Tra-1-60-
positive sorted Fucci-hESCs and observed that Smad2/3 bound
specifically to endoderm genes in early G1 (Figure 3A; Table S2)
and not in any other part of the cell cycle. Furthermore, transfec-
tion of Fucci-hESCs with a luciferase reporter for Smad2/3 tran-
scriptional activity confirmed that the Activin/Nodal-Smad2/3
pathway is less potent during the late G1 phase and G1/S tran-
sition (Figure S2A). These results show that the activity of theFigure 2. The Cell Cycle Directs Differentiation of hESCs
(A–C) Cell-cycle-dependent differentiation of hESCs. qPCR analysis for the expr
incubated for 6 hr in culture condition inductive for three germ layers.
(D and E) Cell cycle regulates the timing of differentiation in hESCs. Fucci-hESCs s
differentiated into (D) endoderm or (E) neuroectoderm and analyzed for germ lay
(F and G) Early G1 phase directs endoderm whereas late G1 promotes neuroecto
markers in FACS sorted Fucci-hESCs incubated for up to two days in culture co
(H) Restricted capacity of differentiation during G1 transition. Left: schematic o
markers in samples (1–4) treated as shown in schematic overview.
(I) Schematic presentation of pancreatic differentiation from sorted or unsorted c
(J) Cell-cycle stage of pluripotent cells affects insulin expression during pancrea
(K) Cell-cycle stage affects foregut marker FoxA2 expression. Immunostaining fo
G1 phase.
(L) Cell-cycle stage of pluripotent cells affects pancreatic differentiation. Early G1
whereas late G1 phase cells reduces pancreatic differentiation.
(M) Cell-cycle stage affects liver differentiation. Expression of liver markers at da
cells that were used during initial endoderm differentiation. All data are shown
represents 100 mm.
See also Figure S1.Activin/Nodal signaling pathway is cell-cycle dependent and
suggest the existence of mechanisms controlling activity/bind-
ing of Smad2/3 during cell-cycle progression.
Because Smad2/3 binding to endoderm loci was blocked dur-
ing the change from early to late G1 phase, we hypothesized that
factors specifically expressed during this cell-cycle phase could
control Activin/Nodal-Smad2/3 pathway. Cyclin D proteins rep-
resented interesting candidates because they are central for
coordinating G1 progression in conjunction with their catalytic
partners CDK4/6. Furthermore, cyclin D1–3 proteins are
expressed in hESCs (Figures S2C–S2E; Table S3) as shown by
others (Neganova et al., 2009) and exhibit a cell-cycle-depen-
dent expression in hESCs peaking at late G1 and G1/S phase
(Figure S2B) when transcriptional activity of Activin/Nodal
signaling pathway is diminished (Figure S2A). Therefore, we
decided to study the pattern of cyclin D expression during
germ layer specification in vitro. Western blot and qPCR ana-
lyses showed that differentiation of hESCs toward neuroecto-
derm resulted in a rapid induction of all three cyclin Ds (Figures
3B, S2F, and S2G), whereas endoderm differentiation (Figures
3B, S2H, and S2I) was accompanied by a decrease in cyclin
D1 and low expression of cyclin D2/D3. Mesoderm differentia-
tion showed an upregulation of cyclin D2, whereas cyclin D1
and D3 exhibited a minor decrease (Figures 3B, S2J, and S2K).
Thus, cyclin Ds are highly expressed during lineage specification
that require Activin/Nodal signaling inhibition (neuroectoderm)
whereas their expression is lower during specification of lineages
requiring Activin/Nodal signaling activity (endoderm and meso-
derm). Together, these data demonstrate that each germ layer
is associated with a specific level/pattern of cyclin D expression.
These observations prompted us to study the function of
cyclin D proteins in hESCs. For that, we stably knocked down
the expression of the three cyclin Ds in all possible combinations
(Figures S3A–S3D). Single-knockdown hESC lines (ShD1-,
ShD2-, and ShD3-hESCs) were able to self-renew, although
we observed a moderate increase in expression of differentia-
tion markers, especially mesoderm/endoderm genes (data not
shown). Double-knockdown hESCs (ShD1D2, ShD2D3, and
ShD1D3-hESCs) showed a propensity for spontaneous dif-
ferentiation into cells expressing endoderm markers, whereasession of germ layer markers in FACS sorted Tra-1-60-positive FUCCI-hESCs
orted into early G1 phase, late G1, G1/S transition, or S/G2/M phase cells were
er and pluripotency marker expression at different time points by qPCR.
derm differentiation. Flow cytometry analysis for the expression of germ layer
ndition inductive for (F) endoderm or (G) neuroectoderm differentiation.
verview of experimental approach. Right: qPCR analysis of neuroectoderm
ells.
tic differentiation. Immunostaining of insulin during pancreatic differentiation.
r FoxA2 at day 8 of hepatic differentiation of hESCs sorted in early G1 or late
phase cells differentiating into endoderm improves pancreatic differentiation,
y 25 of hepatic differentiation shows variability of developmental potential for
as mean ± SD (n = 3). Student’s t test was performed. *p < 0.05. Scale bar
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Figure 3. Cyclin Ds Are Necessary for Pluripotency
(A) Cell-cycle-dependent binding of Smad2/3 to endoderm genes. ChIP analyses in Tra-1-60+ sorted FUCCI-hESCs showing Smad2/3 binding on endoderm
genes.
(B) Cyclin D expression during early differentiation of hESCs. Cyclin D1-3 protein expression during days 1–3 of neuroectoderm, endoderm, and mesoderm
differentiation shown by western blot analysis.
(C) Morphology of cyclin D double knockdown. Representative colonies of shRNA Scramble and cyclin D double-knockdown cells.
(D) Triple knockdown of cyclin D causes endoderm differentiation. cyclin D1/3 double-knockdown cells were transfected with a cyclin D2 shRNA construct
expressing GFP and then FACS sorted for qPCR analyses.
(E) Triple knockdown of cyclin D causes loss of pluripotency markers. Immunofluorescence microscopy analyses for Oct4, Nanog, and Sox2 expression (red) in
cyclin D triple-knockdown hESCs (green / arrows).
(legend continued on next page)
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Figure 4. Cyclin D Overexpression in hESCs Induces Neuroectoderm Differentiation
(A) Morphology of cyclin D overexpression (OE). Representative colonies of GFP OE and cyclin D OE hESCs.
(B andC) Cyclin DOE overexpression causes neuroectoderm differentiation and decreases endodermmarkers. Expression of neuroectodermmarkers in cyclin D
overexpressing cells shown by qPCR (B) or western blot (C).
(D and E) Cyclin Ds repress endoderm loci. Luciferase constructs with Sox17 (D) or GSC (E) promoter regions containing Smad2/3 binding sites were
cotransfected with cyclin D OE constructs, then differentiated into endoderm for 48 hr and analyzed for luciferase activity.
(F) Cyclin Ds repress the initiation of endoderm differentiation in early G1 phase. Fucci-hESCs transfected with cyclin D OE constructs were sorted into early
G1 phase and analyzed for marker expression by flow cytometry after endoderm differentiation.
(G) Cyclin D knockdown causes the accumulation of Smad2/3 on chromatin. Relative amount of Smad2/3 protein in cytoplasm and on chromatin in cyclin D1-3
knockdown cells compared to Scramble shRNA overexpressing cells.
(H) Cyclin D overexpression results in Smad2/3 accumulation in the cytoplasm. Smad2/3 localization in cytoplasm and on chromatin was analyzed in cyclin D1,
D2, and D3 overexpressing cells by western blot. All data are shown as mean ± SD. (n = 3). Student’s t test was performed. *p < 0.05.
See also Figure S4.pluripotency and neuroectoderm marker expression was sys-
tematically diminished (Figures 3C, 3D, 3F, and S3E). Further-
more, double-knockdown hESCs displayed a diminished capac-
ity to differentiate into neuroectoderm and an increased capacity
to differentiate into endoderm/mesoderm (Figures S3F–S3H;
Table S4). Finally, triple-knockdown hESCs (shD1D2D3-hESCs)
could not be expanded in vitro suggesting an essential function
for cyclin Ds in pluripotency and/or self-renewal. To bypass this
limitation, GFP-expressing knockdown constructs were transi-
tory transfected into cyclin D double-knockdown cells showing(F) Double knockdown of cyclin D causes endoderm differentiation and blocks ne
for germ layer marker expression by western blot.
(G) Triple knockdown of cyclin D causes endoderm differentiation. Cyclin D1/3
expressing GFP and then FACS sorted for western blot analyses. UD, undiffere
100 mm.
See also Figures S2 and S3.that decreased expression of all three cyclin Ds resulted in the
loss of pluripotency markers while inducing differentiation into
endoderm (Figures 3D, 3E, 3G, and S3I–S3L). Taken together,
these data demonstrate that cyclin Ds are necessary to maintain
pluripotency in hESCs by limiting their capacity to differentiate
into endoderm.
We then performed the opposite experiments by stably over-
expressing cyclin Ds in hESCs (Figures 4A and S4A–S4D). The
resulting hESCs (OED-hESCs) maintained self-renewal and plu-
ripotency, but showed an increase in neuroectoderm markeruroectoderm differentiation. Cyclin D double-knockdown cells were analyzed
double-knockdown cells were transfected with a cyclin D2 shRNA construct
ntiated cells. Student’s t test was performed. *p < 0.05. Scale bar represents
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expression (Figures 4B and 4C). Furthermore, cyclin OED-
hESCs display an enhanced capacity to differentiate into
neuroectoderm (Figure S4F) and have a limited capacity to differ-
entiate into mesoderm/endoderm (Figures S4G and S4H).
Collectively, these gain of function experiments show that cyclin
Ds promote neuroectoderm differentiation while being able to
inhibit endoderm differentiation induced by Activin/Nodal
signaling. Therefore, cyclin Ds could inhibit the activity associ-
ated with Activin/Nodal signaling especially in late G1 when
they are highly expressed.
Cyclin Ds Control the Transcriptional Activity of
Smad2/3
We then decided to further investigate the molecular mecha-
nisms by which cyclin D could control Activin/Nodal signaling.
Smad2/3 act as main effectors of this pathway and thus repre-
sent obvious candidates for this kind of regulation. Accordingly,
we observed that cyclin D overexpression decreased Smad2/3
transcriptional activity in hESCs (Figure S4E) and in endoderm
cells (Figures 4D and 4E). Constitutive overexpression of cyclin
Ds also decreased the propensity of early G1 hESCs to initiate
endoderm differentiation (Figure 4F) and reduced the number
of early G1 phase cells (11.7% in PTP6, 5.8% in OE cyclin D1,
6.3% in OE cyclin D2, and 7.5% in OE cyclin D3) while
increasing late G1 phase cells (15.8% in PTP6, 18.6% in OE
cyclin D1, 17.9% in OE cyclin D2, and 17.2% in OE cyclin D3).
Finally, western blot analyses revealed that knockdown in cyclin
D expression resulted in an increase in Smad2/3 proteins local-
ized on chromatin, whereas overexpression of cyclin D had the
opposite effect (Figures 4G and 4H). Therefore, the level of
cyclin D proteins appears to modulate the shuttling of
Smad2/3 in and out of the nucleus. To validate these observa-
tions, late G1-hESCs were transitorily transfected with a
Smad2 protein containing a nuclear localization signal (NLS)
(Lo and Massague´, 1999) and the resulting cells were induced
to differentiate into endoderm. qPCR analyses 6 hr after sorting
(Figure S4I) or flow cytometry after 24–48 hr of differentiation
(Figure S4J) show that this constitutive nuclear Smad2 was
able to induce the expression of endoderm markers in late G1
hESCs thereby reinforcing the hypothesis that the cell fate
restriction observed during cell-cycle progression could be
associated with Smad2/3 cellular localization. Importantly,
coimmunoprecipitation analyses showed that cyclin D1/D2/D3
interact with Smad2/3 in hESCs (Figures 5A and 5B) suggesting
that nuclear transport of Smad2/3 could be controlled by this
interaction. Interestingly, a previous study in a cancer cell line
has shown that CDK4/6 could control the transcriptional activity
of Smad2/3 (Matsuura et al., 2004). In accordance, overexpres-
sion of a mutant form of cyclin D1 (T156A) known to inhibit the
catalytic activity of CDK4/6 (Diehl and Sherr, 1997) increase
the expression of endoderm and mesoderm markers in hESCs
(Figure S5A). Furthermore, the same cells display an increased
capacity to differentiate into mesoderm/endoderm and a
decreased capacity to express neuroectodermmarkers (Figures
S5B–S5D) when grown in the corresponding inductive condi-
tions. Together, these results suggest that cyclin D-CDK4/6
inhibit the transcriptional activity of Activin signaling by control-
ling the cellular localization of Smad2/3.142 Cell 155, 135–147, September 26, 2013 ª2013 Elsevier Inc.To further investigate the molecular mechanisms involved in
this regulation, we specifically inhibited CDK4/6 in hESCs using
the small molecule PD0332991 (Fry et al., 2004) and observed an
increase in Smad2/3 localization to the chromatin fraction (Fig-
ure 5C). Inhibition of CDK4/6 in late G1 phase also resulted in
an increase in Smad2/3-dependent transcription (Figure 5D)
and partially removed the mechanism blocking endoderm differ-
entiation in late G1 (Figures 5E and 5F). Taken together, these
data suggest that cyclin D/CDK activity could regulate endo-
derm specification by controlling the transport of Smad2/3 into
the nucleus. Because Smad2/3 nuclear shuttling is mediated
by posttranslational modifications (Kretzschmar et al., 1999),
we investigated the subcellular localization and phosphorylation
status of Smad2 and Smad3 during cell-cycle progression (Fig-
ure 6A). Western blot showed that Smad2 and Smad3 are both
specifically phosphorylated in their linker region in late G1
when they were excluded from the chromatin (Figure 6A). On
the other hand, Smad2/3 proteins were phosphorylated in their
MH2 region (P-S465/467) in early G1when theyweremore abun-
dant on the chromatin. Moreover, inhibition of CDK4/6 activity
resulted in the loss of Smad2/3 linker region phosphorylation
and accumulation of Smad2/3 onto the chromatin (Figure 6A).
Consequently, CDK4/6 appear to regulate Smad2/3 nuclear
shuttling in late G1 of hESCs by phosphorylating specific resi-
dues of their linker regions. To confirm these observations, we
overexpressed in late G1 hESCs mutant forms of Smad2/3
devoid of phosphorylation sites in the linker region (Smad2-
EPSM: T220V, S245A, S250A, S250A; Smad3-EPSM: T178V,
S203A, S207A, S212A). Western blot analyses indicated that
only Smad2/3-EPSM proteins accumulated onto chromatin,
whereas wild-type Smad2/3 remained in the cytoplasm (Fig-
ure 6B). Similarly, Smad2/3-EPSM overexpressing hESCs were
more prone to differentiate into endoderm when compared to
late G1-hESCs overexpressing Smad2/3 (Figures 6C and 6D).
Nevertheless, inhibition of CDK4/6 by PD0332991 improved
endoderm differentiation of late G1-hESCs expressing Smad2
or Smad3 (Figure 6C). Finally, we analyzed the transcriptional
activity of different forms of Smad2/3-EPSM mutants in late
G1-hESCs taking advantage of the SEB4 reporter gene. These
experiments revealed that phosphorylation of Smad2/3 at the
linker region reduces their transcriptional activity (Figures 6E
and 6F), whereas a reversion of specific phosphorylation sites
to their wild-type residue (A212S, V178T) partially restored
Smad3 sensitivity to cyclin D-CDK4/6-mediated phosphoryla-
tion (Figure 6E). These results demonstrate that cyclin
D-CDK4/6 regulate Smad2/3 transcriptional activity in a cell-
cycle phase-dependent manner by phosphorylating specific
sites of the Smad2/3 linker regions to block their entry into the
nucleus.
Manipulating the Activity of Cyclin D-CDK4/6 Enables
Differentiation of hIPSCs into Endoderm Cells without
the Need of Exogenous Activin
Interestingly, hESCs grown in the presence of PD0332991 grad-
ually differentiated as shown by the decrease in pluripotency
marker expression and by the increase in meso/endoderm
markers (Figures 7A–7C and S5E; Table S5). In addition, we
observed that endoderm cells induced by PD0332991 were
Figure 5. Cyclin D/CDK4/6 Control Smad2/3 Transcriptional Activity
(A) Smad2/3 interacts with cyclin D proteins. Smad2/3 was immunoprecipitated and analyzed for the presence of cyclin D1–3 by western blot.
(B) Cyclin D proteins interact with Smad2/3. Cyclin D1–3 were immunoprecipitated and analyzed for the presence of Smad2/3 by western blot.
(C) CDK4/6 inhibition by small molecule results in Smad2/3 accumulation on chromatin. hESCs cells were treated with CDK4/6 inhibitor (CDKi or 0.75 mM
PD0332991) for 2 hr or 8 hr and then Smad2/3 localization in cytoplasm and on chromatin was analyzed using western blot.
(D) Smad2/3 transcriptional activity is repressed in late G1 phase by CDK4/6. Left: schematic overview of the experiment. Right: FUCCI-hESCs were transfected
with a Smad2/3-dependent Luciferase expression construct and incubated with Activin A in the presence or absence of 0.75 mM PD0332991.
(E and F) CDK4/6 inhibition partially removes the endoderm differentiation blockage from late G1 phase cells. Sorted FUCCI-hESCs were differentiated into
endoderm in the presence or absence of 0.75 mMPD0332991 and analyzed by qPCR (E) after 6 hr or flow cytometry (F) after 1–2 days of endoderm differentiation.
Student’s t test was performed. *p < 0.05.able to differentiate further into hepatic and pancreatic progeni-
tors (Figures 7D–7F and S5F). These observations prompted us
to develop a protocol of endoderm differentiation taking advan-
tage of the PD0332991 inhibitor. For that, we tested the effect of
different combinations of Activin, BMP4, FGF2, and PD0332991
(Figure 7C and data not shown) on endoderm differentiation of
hESCs and observed that this inhibitor decreased the need of
exogenous Activin in our culture conditions. This study resulted
in a protocol of endoderm differentiation in which exogenous
Activin was replaced by PD0332991. To further validate this
protocol, three different hIPSC lines were grown in defined cul-
ture conditions supplemented with PD0332991/FGF2/BMP4/
LY29004 for 6 days. hIPSCs grown in these culture conditions
differentiated into endoderm cells as shown by the decrease in
pluripotency markers and the specific increase in endoderm
markers (Figure S6). Furthermore, the resulting endoderm cells
were able to differentiate further into cells expressing hepatic
and pancreatic markers (Figures S7A–S7H). Finally, we alsoapplied this protocol to hIPSCs resistant to conventional
methods of differentiation and observed that chemical inhibition
of CDK4/6-cyclin Ds significantly improved the capacity of
these lines to differentiate into endoderm derivatives thereby
allowing the generation of pancreatic and hepatic cells (Figures
S7I–S7M). Considered together, these results show that manip-
ulation of cyclin D-CDK4/6 activity can be used to direct differen-
tiation of hPSCs toward the endoderm germ layers bypassing
the need of exogenous Activin and the usual variability between
lines. These results also showed that the function of cyclin D in
cell fate choice of hESCs is conserved in hIPSCs and thus that
the mechanisms revealed by our study could be applied to a
broad number of human pluripotent stem cells.
DISCUSSION
Here, we have uncovered mechanisms by which the cell cycle
can control the activity of signaling pathways directing cellCell 155, 135–147, September 26, 2013 ª2013 Elsevier Inc. 143
Figure 6. Cyclin D-CDK4/6 Regulates Smad2/3 Shuttling in hPSCs by Linker Phosphorylation
(A) Smad2/3 intracellular localization and phosphorylation during cell-cycle progression depends on CDK4/6. Cytoplasm and chromatin were isolated from
sorted Fucci-hESCs and analyzed by western blot.
(B) Smad2/3 phosphorylation by CDK4/6 regulates Smad2/3 localization to chromatin. Cytoplasmic and chromatin fractions were isolated from H9 cells 48 hr
after transfection with Flag-tagged Smad2/3 constructs.
(C andD) Sorted Smad2/3 linker phosphorylationmutants can initiate endoderm in lateG1 phase. Fucci-hESCs transfectedwith Smad2/3 constructs were sorted
into late G1 cells, and analyzed by qPCR after 6 hr of endoderm differentiation (C) or flow cytometry after 1–2 days of endoderm differentiation (D).
(E and F) Smad2/3 phosphorylation in linker residues by CDK4/6 blocks Smad2/3 transcriptional activity. FUCCI-hESCs were cotransfected with SBE4-Luc
construct together with Smad3 mutant constructs (E) or Smad2 mutant constructs (F), sorted after 48 hr into late G1 phase and analyzed for luciferase activity.
CDK4/6 was inhibited by 0.75 mM PD0332991 for 6 hr prior to analysis. Student’s t test was performed. *p < 0.05.
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Figure 7. CDKi Treatment Induces Differentiation of hPSCs
(A) Representative colonies of untreated hESCs and CDKi (0.75 mM PD0332991)-treated cells.
(B) CDK4/6 inhibition results in endoderm differentiation. hESCs grown for 6 days in the presence of CDKi (0.75 mMPD0332991) were analyzed for the expression
of germ layer markers using immunofluorescence microscopy.
(C) CDK4/6 can replace Activin A during endoderm differentiation. H9 cells were incubated in the presence or absence of 0.75 mM CDKi in standard endoderm
differentiation conditions and analyzed for Sox17 expression by qPCR.
(D and E) Endoderm cells generated by CDKi can give rise to cells expressing hepatic markers. CDKi-produced endoderm was grown for 25 days in culture
conditions for hepatic differentiation and then the expression of hepatocyte markers was analyzed using qPCR (D) or immunostaining (E).
(F) Endoderm generated by CDKi can give rise to pancreatic cells. CDKi produced endoderm was grown for 18 days in culture conditions for pancreatic
differentiation and then the expression of pancreatic markers was analyzed using qPCR (D) or immunostaining (F). Scale bar represents 100 mm. All data are
shown as mean ± SD (n = 3). UD, undifferentiated cells.
See also Figures S5, S6, S7, and Table S5.fate choice. These mechanisms are orchestrated by cyclin
D-CDK4/6 complex that limits the nuclear localization of key
signaling effectors such as Smad2/3. This model of regulation
implies that cell fate choice primarily occurs during the narrow
window of G1 phase when cyclin D proteins are dynamically ex-
pressed. Accordingly, endoderm induction is only possible in
early G1 when the level of cyclin D is low, allowing Smad2/3 to
bind and to activate endoderm genes. Cyclin D expression in
late G1 results in activation of CDK4/6 that bind Smad2/3 pro-
teins and phosphorylate their linker region. The phosphorylation
of Smad2/3 blocks their entry into the nucleus and therebymakes late G1 cells only receptive for neuroectoderm initiation.
In agreement with the expression of cyclin D proteins, differenti-
ation of ESCs is also accompanied by a change in G1 length
(Coronado et al., 2013), and hESCs differentiating into endoderm
display a longer G1 phase when compared to hESCs grown in
culture conditions inductive for neuroectoderm specification
(data not shown). Furthermore, lengthening of the G1 phase is
associated with an increase in the population of hESCs in early
G1 phase and thus with an increase in the number of cells spe-
cifically prone to endoderm differentiation. These observations
imply that manipulating cell-cycle regulators could enable aCell 155, 135–147, September 26, 2013 ª2013 Elsevier Inc. 145
controlled differentiation of stem cells. Accordingly, inhibiting
CDK4/6 in hPSCs with a small molecule increases G1 length
while inducing endoderm differentiation. Therefore, our study
represents a first step toward the development of a method of
differentiation in which simple manipulation of the cell cycle
using small molecules could direct differentiation of pluripotent
stem cells toward specific cell types without the need of exoge-
nous growth factors.
Expression studies in the mouse embryo showed that cyclin
Ds have a tissue-specific expression during gastrulation (Wianny
et al., 1998). Mesoderm expresses cyclin D1/D2, neuroectoderm
cyclin D1/D2, and endoderm a low level of cyclin D2, whereas
cyclin D3 is specifically expressed in the trophectoderm. There-
fore, the expression pattern of cyclin Ds during gastrulation
mimic the expression of cyclin Ds during in vitro differentiation
of hESCs, thereby suggesting that the mechanisms uncovered
by our study might be transferable to the gastrulating embryo.
However, genetic studies of individual cell-cycle regulators
have been less conclusive and total absence of cyclin D in the
mouse only leads to midgestation lethality (Kozar et al., 2004).
Similar phenotypes were observed in embryos mutant for cyclin
E or CDK2/4/6 suggesting that these factors are dispensable for
early development. These results contrast with the broad num-
ber of studies that have shown the importance of these factors
in established or primary cells in vitro. Furthermore, the impor-
tance of cell-cycle regulation in organogenesis has been identi-
fied in a diversity of systems (Fuchs, 2009; Li and Clevers, 2010).
Therefore, it has been suggested that the absence of cyclin Ds in
early mouse embryo could be rescued in part by CDK2-cyclin E
that would compensate the absence of CDK4/6 activity by regu-
lating the phosphorylation of pRB. Thus, the function of cyclin D
in vivo could be masked by redundant and aberrant mecha-
nisms. Species divergence between human and mice could
also explain the apparent difference between our data generated
with hESCs and the lack of cyclin D function in early mouse
embryo. Indeed, there is growing evidence that part of themech-
anisms controlling early development could differ between the
two species. For instance, FGF signaling, which is known to pro-
mote proliferation, plays an essential role in specification of
extraembryonic tissue in mouse blastocyst, whereas its inhibi-
tion has no effect in human embryo (Kuijk et al., 2012; Roode
et al., 2012). Systematic studies on mEpiSCs could help to un-
cover the molecular basis for such differences and the existence
of compensatory mechanisms specific to the mouse.
The interconnection of cell fate decisions and cell cycle re-
vealed by our findings could also be relevant for stem cells in
developing organs. Indeed, functional studies performed in the
cortex and retina have demonstrated that loss of function of
cyclin D/CDK results in the lengthening of G1 phase and is
always accompanied by increased differentiation of neuronal
stem cells specifically into neurons (Lange and Calegari, 2010;
Lange et al., 2009). More recently, in vitro studies have shown
that the length of G1 phase increases upon differentiation of
neuronal stem cells in vitro, whereas inhibition of CDK4 induces
their differentiation (Roccio et al., 2013). Similarly, absence of
cyclin Ds or CDK4/6 results in premature differentiation of he-
matopoietic stem cells (Lange and Calegari, 2010). Considered
together, these results suggest that the length of G1 phase,146 Cell 155, 135–147, September 26, 2013 ª2013 Elsevier Inc.and thus cyclin D activity, defines the capacity of multipotent
stem cells to differentiate in vivo. Such mechanisms would be
essential to synchronize proliferation and differentiate tissue
specific stem cells into particular lineages. Thus, our findings
could not only start to uncover the molecular mechanisms that
interconnect the cell cycle and cell fate decisions in hESCs
but could also be relevant to understand how proliferation and
differentiation of adult stem cells is coordinated in tissue
homeostasis.
EXPERIMENTAL PROCEDURES
Cell Culture of hESCs, hIPSCs, mEpiSCs, and mESCs
hESCs (H9 from WiCell) were used for all the experiments unless otherwise
stated. H9 cells were grown in defined culture conditions as described previ-
ously (Brons et al., 2007). H9 cells were passaged weekly using collagenase IV
and maintained in chemically defined medium (CDM) supplemented with
Activin A (10 ng/ml) and FGF2 (12 ng/ml). hIPSCs (IPS40 and BBHX8; Vallier
et al., 2009b; A1ATD1) were grown in culture conditions as described in the
Extended Experimental Procedures.
Differentiation of hESCs and IPSCs
hESCs were differentiated into neuroectoderm, endoderm, and mesoderm as
described previously (Vallier et al., 2009b), hIPSCs and hESCs were differen-
tiated into endoderm, pancreatic cells, and to hepatocytes as described in
the Extended Experimental Procedures.
Cell Sorting by FACS
FACS was performed as described before (Sakaue-Sawano et al., 2008). In
sum, hESCswere washedwith PBS and detached from the plate by incubating
them for 10 min at 37C in cell dissociation buffer (GIBCO). Cells were washed
with cold PBS and then subjected to FACS with a Beckman Coulter MoFlo
MLS high-speed cell sorter, using parameters described previously (Sakaue-
Sawano et al., 2008).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and five tables and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2013.08.031.
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